atai life sciences nv - ATAI
ATAI
Close Chg Chg %
4.63 0.02 0.43%
Closed Market
4.65
+0.02 (0.43%)
Volume: 2.71M
Last Updated:
Sep 15, 2025, 4:00 PM EDT
Company Overview: atai life sciences nv - ATAI
ATAI Key Data
| Open $4.64 | Day Range 4.50 - 4.72 |
| 52 Week Range 1.03 - 5.34 | Market Cap $992.38M |
| Shares Outstanding 214.34M | Public Float 136.72M |
| Beta 1.56 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.81 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 4.92M |
ATAI Performance
| 1 Week | 0.43% | ||
| 1 Month | 19.85% | ||
| 3 Months | 120.38% | ||
| 1 Year | 257.69% | ||
| 5 Years | N/A |
ATAI Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About atai life sciences nv - ATAI
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
ATAI At a Glance
ATAI Life Sciences NV
Prof. J.H. Bavincklaan 7
Amstelveen, Noord-Holland 1183 AT
| Phone | N/A | Revenue | 308.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -149,269,000.00 | |
| Sector | Health Technology | Employees | 54 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ATAI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 691.60 |
| Price to Book Ratio | 1.921 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.621 |
| Enterprise Value to Sales | 537.811 |
| Total Debt to Enterprise Value | 0.149 |
ATAI Efficiency
| Revenue/Employee | 5,703.704 |
| Income Per Employee | -2,764,240.741 |
| Receivables Turnover | 0.228 |
| Total Asset Turnover | 0.001 |
ATAI Liquidity
| Current Ratio | 3.211 |
| Quick Ratio | 3.211 |
| Cash Ratio | 2.899 |
ATAI Profitability
| Gross Margin | -53.571 |
| Operating Margin | -33,341.234 |
| Pretax Margin | -48,353.896 |
| Net Margin | -48,463.961 |
| Return on Assets | -65.922 |
| Return on Equity | -83.098 |
| Return on Total Capital | -105.862 |
| Return on Invested Capital | -76.484 |
ATAI Capital Structure
| Total Debt to Total Equity | 21.244 |
| Total Debt to Total Capital | 17.522 |
| Total Debt to Total Assets | 15.501 |
| Long-Term Debt to Equity | 12.782 |
| Long-Term Debt to Total Capital | 10.542 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Atai Life Sciences Nv - ATAI
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 20.38M | 233.00K | 314.00K | 308.00K | |
Sales Growth
| - | -98.86% | +34.76% | -1.91% | |
Cost of Goods Sold (COGS) incl D&A
| 47.00K | 168.00K | 319.00K | 473.00K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 47.00K | 168.00K | 319.00K | 473.00K | |
Depreciation
| 47.00K | 168.00K | 319.00K | 273.00K | |
Amortization of Intangibles
| - | - | - | 200.00K | - |
COGS Growth
| +95.83% | +257.45% | +89.88% | +48.28% | |
Gross Income
| 20.33M | 65.00K | (5.00K) | (165.00K) | |
Gross Income Growth
| +84,804.17% | -99.68% | -107.69% | -3,200.00% | |
Gross Profit Margin
| +99.77% | +27.90% | -1.59% | -53.57% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 140.65M | 144.50M | 125.47M | 102.53M | |
Research & Development
| 47.91M | 74.15M | 61.88M | 54.98M | |
Other SG&A
| 92.75M | 70.35M | 63.58M | 47.54M | |
SGA Growth
| +35.07% | +2.73% | -13.17% | -18.28% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 24.67M | (2.36M) | (85.63M) | 42.15M | |
EBIT after Unusual Expense
| (144.99M) | (142.07M) | (39.84M) | (144.84M) | |
Non Operating Income/Expense
| 8.39M | 6.89M | 3.21M | (969.00K) | |
Non-Operating Interest Income
| 205.00K | 548.00K | 1.85M | 778.00K | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 2.66M | 3.12M | - |
Interest Expense Growth
| - | - | - | +17.62% | - |
Gross Interest Expense
| - | - | 2.66M | 3.12M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (136.60M) | (135.18M) | (39.29M) | (148.93M) | |
Pretax Income Growth
| -34.17% | +1.04% | +70.94% | -279.09% | |
Pretax Margin
| -670.40% | -58,018.03% | -12,511.46% | -48,353.90% | |
Income Tax
| (3.99M) | 6.23M | 1.02M | (881.00K) | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| 1.12M | 1.16M | 1.02M | (356.00K) | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | (5.11M) | 5.07M | - |
Income Tax Credits
| - | - | - | 525.00K | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (174.24M) | (157.42M) | (43.90M) | (150.05M) | |
Minority Interest Expense
| (6.44M) | (5.03M) | (3.67M) | (780.00K) | |
Net Income
| (167.81M) | (152.39M) | (40.22M) | (149.27M) | |
Net Income Growth
| +1.20% | +9.19% | +73.60% | -271.09% | |
Net Margin Growth
| -823.56% | -65,401.29% | -12,810.19% | -48,463.96% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (167.81M) | (152.39M) | (40.22M) | (149.27M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (167.81M) | (152.39M) | (40.22M) | (149.27M) | |
EPS (Basic)
| -1.0444 | -0.9786 | -0.2532 | -0.932 | |
EPS (Basic) Growth
| +96.43% | +6.30% | +74.13% | -268.09% | |
Basic Shares Outstanding
| 160.68M | 155.72M | 158.83M | 160.16M | |
EPS (Diluted)
| -1.0444 | -0.9786 | -0.2532 | -0.932 | |
EPS (Diluted) Growth
| +96.43% | +6.30% | +74.13% | -268.09% | |
Diluted Shares Outstanding
| 160.68M | 155.72M | 158.83M | 160.16M | |
EBITDA
| (120.28M) | (144.26M) | (125.15M) | (102.22M) | |
EBITDA Growth
| -15.50% | -19.94% | +13.25% | +18.32% | |
EBITDA Margin
| -590.29% | -61,915.02% | -39,857.32% | -33,187.66% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 11.00 | |
| Number of Ratings | 9 | Current Quarters Estimate | -0.109 | |
| FY Report Date | 09 / 2025 | Current Year's Estimate | -0.482 | |
| Last Quarter’s Earnings | -0.14 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.93 | Next Fiscal Year Estimate | -0.435 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 9 | 9 | 8 |
| Mean Estimate | -0.11 | -0.11 | -0.48 | -0.44 |
| High Estimates | -0.08 | -0.07 | -0.43 | -0.28 |
| Low Estimate | -0.13 | -0.19 | -0.58 | -0.90 |
| Coefficient of Variance | -18.67 | -35.81 | -11.89 | -45.35 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 9 | 9 | 9 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Atai Life Sciences Nv - ATAI
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Atai Life Sciences Nv - ATAI
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 25, 2025 | Srinivas G. Rao See Remarks | 212,942 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.35 per share | 287,471.70 |
| Mar 25, 2025 | Glenn Short Chief Scientific Officer | 42,333 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.35 per share | 57,149.55 |
| Mar 25, 2025 | Apeiron Partners | 42,369,415 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.4 per share | 59,317,181.00 |
| Mar 25, 2025 | Kevin Craig Chief Medical Officer | 8,437 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.35 per share | 11,389.95 |
| Mar 25, 2025 | Anne Johnson Chief Financial Officer | 140,045 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.35 per share | 189,060.75 |
| Mar 25, 2025 | Sahil Kirpekar Chief Business Officer | 115,636 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.35 per share | 156,108.60 |
| Mar 21, 2025 | Srinivas G. Rao See Remarks | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 21, 2025 | Glenn Short Chief Scientific Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 21, 2025 | Kevin Craig Chief Medical Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 21, 2025 | Anne Johnson Chief Financial Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 21, 2025 | Sahil Kirpekar Chief Business Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Gerd G. Kochendoerfer Chief Operating Officer | 1,450,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |